Search Results - Martin Erlanson

  • Showing 1 - 4 results of 4
Refine Results
  1. 1

    High risk of cardiovascular side effects after treatment of Hodgkin’s lymphoma – is there a need for intervention in long-term survivors? by Anne Andersson, Gunilla Enblad, Martin Erlanson, Ann-Sofie Johansson, Daniel Molin, Björn Tavelin, Ulf Näslund, Beatrice Melin

    Published in Upsala Journal of Medical Sciences (2021-02-01)
    Get full text
    Article


  2. 2

    Semimethylation is a feature of diffuse large B-cell lymphoma, and subgroups with poor prognosis are characterized by global hypomethylation and short telomere length by Olivia Carlund, Elina Thörn, Pia Osterman, Maja Fors, Andy Dernstedt, Mattias N. E. Forsell, Martin Erlanson, Mattias Landfors, Sofie Degerman, Magnus Hultdin

    Published in Clinical Epigenetics (2024-05-01)
    Get full text
    Article


  3. 3

    Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: result... by Elisa J. Pulczynski, Outi Kuittinen, Martin Erlanson, Hans Hagberg, Alexander Fosså, Mikael Eriksson, Marie Nordstrøm, Bjørn Østenstad, Øystein Fluge, Sirpa Leppä, Bente Fiirgaard, Hanne Bersvendsen, Unn-Merete Fagerli

    Published in Haematologica (2015-04-01)
    Get full text
    Article


  4. 4

    Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up by Elisa Jacobsen Pulczynski, Mikkel Runason Simonsen, Outi Kuittinen, Unn-Merete Fagerli, Martin Erlanson, Øystein Fluge, Sirpa Leppä, Bjørn Østenstad, Alexander Fosså, Mikael Eriksson, Tarec El-Galaly, Hanne Kuitunen, Karin Papworth, Maria Ljungqvist, Martin B. Pedersen, Marjukka Pollari

    Published in Haematologica (2024-03-01)
    Get full text
    Article


Search Tools: